Significantly lower need for blood transfusions associated with post-operatively initiated subcutaneous melagatran/oral ximelagatran compared with enoxaparin [3]

Thrombosis and Haemostasis

Volumn 92, Issue 2, 2004, Pages 428-430

  Eriksson, Bengt I ^a,h   Agnelli, Giancarlo ^b   Cohen, Alexander ^c   Dahl, Ola ^d   Mouret, Patrick ^e   Rosencher, Nadia ^f   Panfilov, Seva ^g   Andersson, Magnus ^g  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF PERUGIA   (Italy)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d Buskerud Central Hospital   (Norway)

^e Frankfurt Höchst City Hospital   (Germany)

^f Cochin University Hospital ^*  (France)

^g ASTRAZENECA R AND D   (Sweden)

^h NONE

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; MELAGATRAN; XIMELAGATRAN;

ANTICOAGULANT THERAPY; BLEEDING; BLOOD TRANSFUSION; BLOOD VOLUME; DRUG EFFICACY; DRUG SAFETY; HUMAN; LETTER; LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; STATISTICAL ANALYSIS; THROMBOEMBOLISM; TIME; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; TREATMENT OUTCOME;

EID: 4444326878     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613733     Document Type: Letter

References (3)

1. Eriksson BI, Agnelli G, Cohen AT, et al. on behalf of the METHRO III Study Group. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. The METHRO III study. Thromb Haemost 2003; 89: 288-96.
2. Eriksson BI, Bergqvist D, Kälebo P, et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 2002; 360: 1441-7.
3. Eriksson BI, Agnelli G, Cohen AT, et al. on behalf of the EXPRESS Study Group. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost 2003; 1: 2490-6.